Search

Your search keyword '"van der Poel, M."' showing total 17 results
Start Over Author "van der Poel, M." Database OAIster
17 results on '"van der Poel, M."'

1. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, Carlos, Stüssi, G, van Norden, Y, Ossenkoppele, G J, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, Carlos, Stüssi, G, van Norden, Y, and Ossenkoppele, G J

Abstract

Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1 inhibitor selinexor to intensive chemotherapy would improve outcome in this population. 102 AML patients > 65 years of age (median 69 (65-80)) were randomly assigned to standard chemotherapy (3 + 7) with or without oral selinexor 60 mg twice weekly (both arms n = 51), days 1-24. In the second cycle, cytarabine 1000 mg/m twice daily, days 1-6 with or without selinexor was given. CR/CRi rates were significantly higher in the control arm than in the investigational arm (80% (95% C.I. 69-91%) vs. 59% (45-72%; p = 0.018), respectively). At 18 months, event-free survival was 45% for the control arm versus 26% for the investigational arm (Cox-p = 0.012) and overall survival 58% vs. 33%, respectively (p = 0.009). AML and infectious complications accounted for an increased death rate in the investigational arm. Irrespective of treatment, MRD status after two cycles appeared to be correlated with survival. We conclude that the addition of selinexor to standard chemotherapy does negatively affect the therapeutic outcome of elderly AML patients. (Netherlands Trial Registry number NL5748 (NTR5902), www.trialregister.nl ).

Published
2022

2. Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds

Author

Janssen, J. (Jeroen), Löwenberg, B. (Bob), Manz, M. (Markus), Bargetzi, M. (Mario), Biemond, B.J. (Bart), Borne, P.A.K. (Peter) von dem, Breems, D.A. (Dimitri), Brouwer, R.E. (Rolf), Chalandon, Y. (Yves), Deeren, D. (Dries), Efthymiou, A. (Anna), Gjertsen, B.-T. (Bjørn-Tore), Graux, C. (Carlos), Gregor, M. (Michael), Heim, D. (Dominik), Hess, U. (Urs), Hoogendoorn, M. (Mels), Jaspers, A. (Aurelie), Jie, A. (Asiong), Jongen-Lavrencic, M. (Mojca), Klein, S. (Saskia), Klift, M. (Marjolein) van der, Kuball, J. (Jürgen), van Lammeren - Venema, D. (Danielle), Legdeur, M.C.J.C. (M. C J C), Loosdrecht, A.A. (Arjan) van de, Maertens, J. (Johan), Kooy, M.M. (Marinus van Marwijk), Moors, I. (Ine), Nijziel, M.R. (Marten), van Obbergh, F. (Florence), Oosterveld, M. (Margriet), Pabst, T. (Thomas), van der Poel, M. (Marjolein), Sinnige, H. (Harm), Spertini, O. (Olivier), Terpstra, W. (Wim), Tick, L.W. (Lidwine), Velden, W.J.F.M. (Walter) van der, Vekemans, M.-C. (Marie-Christiane), Vellenga, E. (Edo), Weerdt, O. (Okke) de, Westerweel, P. (Peter), Stussi, G. (Georg), Norden, Y. (Yvette) van, Ossenkoppele, G.J. (Gert), Janssen, J. (Jeroen), Löwenberg, B. (Bob), Manz, M. (Markus), Bargetzi, M. (Mario), Biemond, B.J. (Bart), Borne, P.A.K. (Peter) von dem, Breems, D.A. (Dimitri), Brouwer, R.E. (Rolf), Chalandon, Y. (Yves), Deeren, D. (Dries), Efthymiou, A. (Anna), Gjertsen, B.-T. (Bjørn-Tore), Graux, C. (Carlos), Gregor, M. (Michael), Heim, D. (Dominik), Hess, U. (Urs), Hoogendoorn, M. (Mels), Jaspers, A. (Aurelie), Jie, A. (Asiong), Jongen-Lavrencic, M. (Mojca), Klein, S. (Saskia), Klift, M. (Marjolein) van der, Kuball, J. (Jürgen), van Lammeren - Venema, D. (Danielle), Legdeur, M.C.J.C. (M. C J C), Loosdrecht, A.A. (Arjan) van de, Maertens, J. (Johan), Kooy, M.M. (Marinus van Marwijk), Moors, I. (Ine), Nijziel, M.R. (Marten), van Obbergh, F. (Florence), Oosterveld, M. (Margriet), Pabst, T. (Thomas), van der Poel, M. (Marjolein), Sinnige, H. (Harm), Spertini, O. (Olivier), Terpstra, W. (Wim), Tick, L.W. (Lidwine), Velden, W.J.F.M. (Walter) van der, Vekemans, M.-C. (Marie-Christiane), Vellenga, E. (Edo), Weerdt, O. (Okke) de, Westerweel, P. (Peter), Stussi, G. (Georg), Norden, Y. (Yvette) van, and Ossenkoppele, G.J. (Gert)

Abstract

Treatment results of AML in elderly patients are unsatisfactory. We hypothesized that addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy may improve outcome in this population. After establishing a safe dose in a run-in phase of the study in 22 patients, 231 eligible patients with AML above 65 years of age (median 70, range 66–81) were randomly assigned in this open label randomized Phase II study to receive standard chemotherapy (3+7) with or without tosedostat at the selected daily dose of 120 mg (n = 116), days 1–21. In the second cycle, patients received cytarabine 1000 mg/m2 twice daily on days 1-6 with or without tosedostat. CR/CRi rates in the 2 arms were not significantly different (69% (95% C.I. 60–77%) vs 64% (55–73%), respectively). At 24 months, event-free survival (EFS) was 20% for the standard arm versus 12% for the tosedostat arm (Cox-p = 0.01) and overall survival (OS) 33% vs 18% respectively (p = 0.006). Infectious complications accounted for an increased early death rate in the tosedostat arm. Atrial fibrillation wa

Published
2021
Full Text
View/download PDF

3. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes

Author

Oran, B, Ahn, KW, Fretham, C, Beitinjaneh, A, Bashey, A, Pawarode, A, Wirk, B, Scott, BL, Savani, BN, Bredeson, C, Weisdorf, D, Marks, DI, Rizzieri, D, Copelan, E, Hildebrandt, GC, Hale, GA, Murthy, HS, Lazarus, HM, Cerny, J, Liesveld, JL, Yared, JA, Yves-Cahn, J, Szer, J, Verdonck, LF, MahmoudAljurf, van der Poel, M, Litzow, M, Kalaycio, M, Grunwald, MR, AngelDiaz, M, Sabloff, M, Kharfan-Dabaja, MA, Majhail, NS, Farhadfar, N, Reshef, R, Olsson, RF, Gale, RP, Nakamura, R, Seo, S, Chhabra, S, Hashmi, S, Farhan, S, Ganguly, S, Nathan, S, TaigaNishihori, Jain, T, VaibhavAgrawal, Bacher, U, Popat, U, Saber, W, Oran, B, Ahn, KW, Fretham, C, Beitinjaneh, A, Bashey, A, Pawarode, A, Wirk, B, Scott, BL, Savani, BN, Bredeson, C, Weisdorf, D, Marks, DI, Rizzieri, D, Copelan, E, Hildebrandt, GC, Hale, GA, Murthy, HS, Lazarus, HM, Cerny, J, Liesveld, JL, Yared, JA, Yves-Cahn, J, Szer, J, Verdonck, LF, MahmoudAljurf, van der Poel, M, Litzow, M, Kalaycio, M, Grunwald, MR, AngelDiaz, M, Sabloff, M, Kharfan-Dabaja, MA, Majhail, NS, Farhadfar, N, Reshef, R, Olsson, RF, Gale, RP, Nakamura, R, Seo, S, Chhabra, S, Hashmi, S, Farhan, S, Ganguly, S, Nathan, S, TaigaNishihori, Jain, T, VaibhavAgrawal, Bacher, U, Popat, U, and Saber, W

Published
2021

4. Comparing practice and outcome of laparoscopic liver resection between high-volume expert centres and nationwide low-to-medium volume centres

Author

Zorgeenheid Vaatchirurgie Zorg, MS CGO, Cancer, Görgec, B., Fichtinger, R. S., Ratti, F., Aghayan, D., Van der Poel, M. J., Al-Jarrah, R., Armstrong, T., Cipriani, F., Fretland, ÅA, Suhool, A., Bemelmans, M., Bosscha, K., Braat, A. E., De Boer, M. T., Dejong, C. H.C., Doornebosch, P. G., Draaisma, W. A., Gerhards, M. F., Gobardhan, P. D., Hagendoorn, J., Kazemier, G., Klaase, J., Leclercq, W. K.G., Liem, M. S., Lips, D. J., Marsman, H. A., Mieog, J. S.D., Molenaar, Q. I., Nieuwenhuijs, V. B., Nota, C. L., Patijn, G. A., Rijken, A. M., Slooter, G. D., Stommel, M. W.J., Swijnenburg, R. J., Tanis, P. J., Te Riele, W. W., Terkivatan, T., Van den Tol, P. M.P., Van den Boezem, P. B., Van der Hoeven, J. A., Vermaas, M., Edwin, B., Aldrighetti, L. A., Van Dam, R. M., Abu Hilal, M., Besselink, M. G., Zorgeenheid Vaatchirurgie Zorg, MS CGO, Cancer, Görgec, B., Fichtinger, R. S., Ratti, F., Aghayan, D., Van der Poel, M. J., Al-Jarrah, R., Armstrong, T., Cipriani, F., Fretland, ÅA, Suhool, A., Bemelmans, M., Bosscha, K., Braat, A. E., De Boer, M. T., Dejong, C. H.C., Doornebosch, P. G., Draaisma, W. A., Gerhards, M. F., Gobardhan, P. D., Hagendoorn, J., Kazemier, G., Klaase, J., Leclercq, W. K.G., Liem, M. S., Lips, D. J., Marsman, H. A., Mieog, J. S.D., Molenaar, Q. I., Nieuwenhuijs, V. B., Nota, C. L., Patijn, G. A., Rijken, A. M., Slooter, G. D., Stommel, M. W.J., Swijnenburg, R. J., Tanis, P. J., Te Riele, W. W., Terkivatan, T., Van den Tol, P. M.P., Van den Boezem, P. B., Van der Hoeven, J. A., Vermaas, M., Edwin, B., Aldrighetti, L. A., Van Dam, R. M., Abu Hilal, M., and Besselink, M. G.

Published
2021

5. Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions

Author

Fransen, N.L. (Nina L.), Hsiao, C.-C. (Cheng-Chih), van der Poel, M. (Marlijn), Engelenburg, H.J. (Hendrik J.), Verdaasdonk, K. (Kim), Vincenten, M.C.J. (Maria C J), Remmerswaal, D. (Daniëlle), Kuhlmann, T. (Tanja), Mason, M.R.J. (Matthew R J), Hamann, J. (Jörg), Smolders, J. (Joost), Huitinga, I. (Inge), Fransen, N.L. (Nina L.), Hsiao, C.-C. (Cheng-Chih), van der Poel, M. (Marlijn), Engelenburg, H.J. (Hendrik J.), Verdaasdonk, K. (Kim), Vincenten, M.C.J. (Maria C J), Remmerswaal, D. (Daniëlle), Kuhlmann, T. (Tanja), Mason, M.R.J. (Matthew R J), Hamann, J. (Jörg), Smolders, J. (Joost), and Huitinga, I. (Inge)

Abstract

Multiple sclerosis is a chronic inflammatory, demyelinating disease, although it has been suggested that in the progressive late phase, inflammatory lesion activity declines. We recently showed in the Netherlands Brain Bank multiple sclerosis-autopsy cohort considerable ongoing inflammatory lesion activity also at the end stage of the disease, based on microglia/macrophage activity. We have now studied the role of T cells in this ongoing inflammatory lesion activity in chronic multiple sclerosis autopsy cases. We quantified T cells and perivascular T-cell cuffing at a standardized location in the medulla oblongata in 146 multiple sclerosis, 20 neurodegenerative control and 20 non-neurological control brain donors. In addition, we quantified CD3+, CD4+, and CD8+ T cells in 140 subcortical white matter lesions. The location of CD8+ T cells in either the perivascular space or the brain parenchyma was determined using CD8/laminin staining and confocal imaging. Finally, we analysed CD8+ T cells, isolated from fresh autopsy tissues from subcortical multiple sclerosis white matter lesions (n = 8), multiple sclerosis normal-app

Published
2020
Full Text
View/download PDF

7. Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

Author

UCL - (SLuc) Centre du cancer, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, UCL - SSS/DDUV/MEXP - Médecine expérimentale, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, Carlos, Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., van der Klift, M., van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W. M., van Rhenen, A., Tick, L., Valk, P., Vekemans, Marie-Christiane, van der Velden, W. J. F. M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B., Havelange, Violaine, Sonet, Anne, UCL - (SLuc) Centre du cancer, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, UCL - SSS/DDUV/MEXP - Médecine expérimentale, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, Carlos, Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., van der Klift, M., van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W. M., van Rhenen, A., Tick, L., Valk, P., Vekemans, Marie-Christiane, van der Velden, W. J. F. M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B., Havelange, Violaine, and Sonet, Anne

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

9. COnsensus statement on Mandatory Measurements in PAncreatic Cancer Trials for systemic treatment of unresectable disease (COMMPACT)

Author

van Rijssen, L. B., ter Veer, E., Besselink, M. G., Mali, R. M. A., Berlin, J., Boeck, S., Bonnetain, F., Conroy, T., Deplanque, G., Goldstein, D., Glimelius, Bengt, Neoptolemos, J. P., Reni, M., Scheithauer, W., van der Meer, J., Wilmink, J. W., van der Poel, M. J., Busch, O. R., van Oijen, M. G. H., van Laarhoven, H. W. M., van Rijssen, L. B., ter Veer, E., Besselink, M. G., Mali, R. M. A., Berlin, J., Boeck, S., Bonnetain, F., Conroy, T., Deplanque, G., Goldstein, D., Glimelius, Bengt, Neoptolemos, J. P., Reni, M., Scheithauer, W., van der Meer, J., Wilmink, J. W., van der Poel, M. J., Busch, O. R., van Oijen, M. G. H., and van Laarhoven, H. W. M.

Published
2017

10. The international diversification of banks and the value of their cross-border M&A advice

Author

Rajamani, Anjana, van der Poel, M, de Jong, Abe, Ongena, S, Rajamani, Anjana, van der Poel, M, de Jong, Abe, and Ongena, S

Abstract

We examine the impact of the international diversification of banks on the value of their advice in 1,705 cross-border merger and acquisition (M&A) transactions. We find that bidders engaging internationally diversified advisors face lower announcement returns. An increase of one standard deviation in advisor diversification is associated with an announcement return lower by 92 basis points for a bidder acquiring a listed target. The lower bidder returns are attributable to the lower synergies of the deals being completed. Our evidence suggests that internationally diversified advisors offer lower-quality advice to their clients, since their reputational concerns are weakened by having access to multiple geographies from which they can derive fee-based income. We present further evidence that financial incentives in the form of the advisor’s involvement in deal financing and market incentives in the form of the potential to gain market share in the bidder country may mitigate some of the negative effects of the international diversification of the advisors.

Published
2017

11. The International Diversification of Banks and the Value of their Cross-Border M&A Advice

Author

de Jong, A., Ongena, S., van der Poel, M., de Jong, A., Ongena, S., and van der Poel, M.

Abstract

This paper investigates the effects of international diversification of banks on the value of their M&A advice. We study bidder returns to 1,253 cross-border M&A announcements. We find that acquirers engaging a more internationally diversified financial advisor generate lower excess returns. Acquirers benefit most from advisors with a greater focus on their home country. These results suggest that the benefits of advisors’ international diversification related to greater economies of scale and scope and the flexibility of allocating deals to the most skilled employee do not outweigh the costs emanating from a lack of country-specific knowledge and greater conflicts of interest.

Published
2010

12. The International Diversification of Banks and the Value of their Cross-Border M&A Advice

Author

de Jong, A., Ongena, S., van der Poel, M., de Jong, A., Ongena, S., and van der Poel, M.

Abstract

This paper investigates the effects of international diversification of banks on the value of their M&A advice. We study bidder returns to 1,253 cross-border M&A announcements. We find that acquirers engaging a more internationally diversified financial advisor generate lower excess returns. Acquirers benefit most from advisors with a greater focus on their home country. These results suggest that the benefits of advisors’ international diversification related to greater economies of scale and scope and the flexibility of allocating deals to the most skilled employee do not outweigh the costs emanating from a lack of country-specific knowledge and greater conflicts of interest.

Published
2010

13. In vitro-differentiated T/natural killer-cell progenitors derived from human CD34+ cells mature in the thymus

Author

Meek, B, Cloosen, S, Borsotti, C, Van Elssen, C H, Vanderlocht, J, Schnijderberg, M C, van der Poel, M W, Leewis, B, Hesselink, R, Manz, M G, Katsura, Y, Kawamoto, H, Germeraad, W T, Bos, G M, Meek, B, Cloosen, S, Borsotti, C, Van Elssen, C H, Vanderlocht, J, Schnijderberg, M C, van der Poel, M W, Leewis, B, Hesselink, R, Manz, M G, Katsura, Y, Kawamoto, H, Germeraad, W T, and Bos, G M

Abstract

Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is a treatment option for patients with hematopoietic malignancies that is hampered by treatment-related morbidity and mortality, in part the result of opportunistic infections, a direct consequence of delayed T-cell recovery. Thymic output can be improved by facilitation of thymic immigration, known to require precommitment of CD34(+) cells. We demonstrate that Delta-like ligand-mediated predifferentiation of mobilized CD34(+) cells in vitro results in a population of thymocyte-like cells arrested at a T/natural killer (NK)-cell progenitor stage. On intrahepatic transfer to Rag2(-/-)gamma(c)(-/-) mice, these cells selectively home to the thymus and differentiate toward surface T-cell receptor-alphabeta(+) mature T cells considerably faster than animals transplanted with noncultured CD34(+) cells. This finding creates the opportunity to develop an early T-cell reconstitution therapy to combine with HSCT.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results